Table of Content

Chapter 1 Introduction
Overview
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Segmentation Breakdown

Chapter 2 Summary and Highlights

Chapter 3 Market Overview
History
Trypanosoma Cruzi
Vector and T. cruzi
Transmission Routes
Clinical Forms
Future Perspectives
Novel Drugs

Chapter 4 Chagas Disease by Drugs
Overview
Benznidazole
Toxicity of Benznidazole
Nifurtimox
Toxicity of Nifurtimox

Chapter 5 Chagas Disease by Diagnosis
Overview
Serology (Antibody Detection)
Molecular Testing

Chapter 6 Competitive Landscape
Competitive Analysis

Chapter 7 Company Profiles
BAYER AG
INSUD PHARMA

Chapter 8 Appendix: Acronyms



List of Figures


Summary Figure : Life Cycle of Trypanosoma Cruzi
Figure 1 : Bayer AG: Annual Revenue, 2021 and 2022
Figure 2 : Bayer AG: Revenue Shares, by Business Unit, 2022
Figure 3 : Bayer AG: Revenue Shares, by Region, 2022

List of Tables


Table 1 : Novel Drugs for Chagas Disease Treatment
Table 2 : Drugs for Chagas Disease
Table 3 : Bayer AG: Company Snapshot
Table 4 : Bayer AG: Annual Revenue, 2021 and 2022
Table 5 : Bayer AG: News
Table 6 : Insud Pharma: Company Snapshot
Table 7 : Insud Pharma: News
Table 8 : Acronyms Used in This Report